NEW YORK – Oslo, Norway-based Vaccibody on Thursday announced that it had entered into a licensing agreement with Roche subsidiary Genentech to develop and commercialize VB10.NEO, Vaccibody's investigational DNA-based, individualized neoantigen vaccine for the treatment of patients with locally advanced or metastatic cancers.